Insili Intelligence (03696) and Luoxin Pharmaceutical (002793.SZ) have reached a strategic AI pharmaceutical cooperation, focusing on research and development of innovative drugs for chronic diseases such as digestion and metabolism

According to the Zhitong Finance App, Insili Intelligence (03696) announced that Insilicon Intelligent Technology (Shanghai) Co., Ltd., a wholly-owned subsidiary of the company, recently signed a strategic cooperation agreement with Luoxin Pharmaceutical (002793.SZ).

According to the strategic cooperation agreement, the two sides plan to establish a long-term strategic partnership around innovative drug research and development, promote the deep integration of artificial intelligence technology with expertise, research data and R&D experience in the field of diseases, and jointly explore innovative drug research and development with clinical value and development potential. The two sides prioritize exploration and cooperation in the fields of digestive diseases, metabolic diseases, and other non-neoplastic chronic diseases, and gradually expand into other disease fields jointly recognized by the two sides based on actual progress.

The two sides promote cooperation in accordance with the principle of “joint evaluation, phased implementation, and project-by-project confirmation”. Relying on their respective resource advantages, technology accumulation and channel capabilities, they achieve complementary advantages and collaborative development, further enhance the company's core competitiveness, and help the company's long-term strategic layout. Specific areas of cooperation include disease research and target discovery, innovative molecule discovery and optimization, research project empowerment, R&D transformation collaboration, technical and professional exchanges, and other cooperation matters agreed upon by both parties.